Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions.
4 affiliations
- 1Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.
- 2GSK, Durham, North Carolina, USA.
- 3GSK, Philadelphia, Pennsylvania, USA.
- 4Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.
Abstract
Chronic hepatitis B (CHB) infection represents a major public health challenge in the US, with substantial unmet needs related to timely diagnosis, treatment, monitoring and disease management. This narrative review explores the CHB landscape in the US, including gaps in patient care, the evolving therapeutic landscape, the clinical utility of serological biomarkers to improve outcomes and the experiences of people living with hepatitis B (PLWHB). Hepatitis B remains underdiagnosed and undertreated in the US, and current efforts are insufficient to meet the associated World Health Organization 2030 elimination targets. Latest guidelines from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, representing a North American perspective, signify a shift towards expanded treatment eligibility criteria and shared decision-making. Nucleos(t)ide analogues (NAs) are the current standard of care in the US, but functional cure is rarely achieved with NAs alone. Novel finite therapies targeting functional cure, such as antisense oligonucleotides, small interfering RNAs, immune modulators and combination or sequential regimens, are under investigation. Because of the unpredictable, complex nature of CHB, biomarkers such as quantitative hepatitis B surface antigen offer prognostic value for treatment decisions and could help guide individualised CHB management. PLWHB experience psychological impacts and health-related concerns, including fear of transmission and hepatitis B virus-related complications. Opportunities for improvement of CHB management include increased screening and linkage to care, development of more treatments targeting functional cure, adoption of serological biomarkers to inform treatment decisions and prioritising the lived experiences and preferences of PLWHB.
Related
- Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
- Artificial Intelligence in Voice Disorders: Current Landscape, Emerging Applications and Future Directions
- Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions
- Artificial intelligence in Saudi otolaryngology research: a scoping review of the current landscape, gaps, and future directions
- Chronic Idiopathic Axonal Polyneuropathy: Current Evidence and Future Directions
BibTeX
@article{cohen2026chronic,
title = {{Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions.}},
author = {Chari Cohen and James Philip Esteban and Shravani Bobde and Robert J Wong},
journal = {Journal of viral hepatitis},
year = {2026},
month = nov,
doi = {10.1111/jvh.70237},
url = {https://europepmc.org/article/MED/42969555},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions.
AU - Chari Cohen
AU - James Philip Esteban
AU - Shravani Bobde
AU - Robert J Wong
PY - 2026
DA - 2026/11/02
JO - Journal of viral hepatitis
DO - 10.1111/jvh.70237
UR - https://europepmc.org/article/MED/42969555
AB - Chronic hepatitis B (CHB) infection represents a major public health challenge in the US, with substantial unmet needs related to timely diagnosis, treatment, monitoring and disease management. This narrative review explores the CHB landscape in the US, including gaps in patient care, the evolving therapeutic landscape, the clinical utility of serological biomarkers to improve outcomes and the experiences of people living with hepatitis B (PLWHB). Hepatitis B remains underdiagnosed and undertreated in the US, and current efforts are insufficient to meet the associated World Health Organization 2030 elimination targets. Latest guidelines from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, representing a North American perspective, signify a shift towards expanded treatment eligibility criteria and shared decision-making. Nucleos(t)ide analogues (NAs) are the current standard of care in the US, but functional cure is rarely achieved with NAs alone. Novel finite therapies targeting functional cure, such as antisense oligonucleotides, small interfering RNAs, immune modulators and combination or sequential regimens, are under investigation. Because of the unpredictable, complex nature of CHB, biomarkers such as quantitative hepatitis B surface antigen offer prognostic value for treatment decisions and could help guide individualised CHB management. PLWHB experience psychological impacts and health-related concerns, including fear of transmission and hepatitis B virus-related complications. Opportunities for improvement of CHB management include increased screening and linkage to care, development of more treatments targeting functional cure, adoption of serological biomarkers to inform treatment decisions and prioritising the lived experiences and preferences of PLWHB.
SN - 1352-0504
SN - 1365-2893
ER -